{'fraction_non_alphanumeric': 0.03387096774193549, 'fraction_numerical': 0.00967741935483871, 'mean_word_length': 5.2727272727272725, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Association between the ATF3 gene and non‐small cell lung cancer

Background:  Non‐small cell lung cancer (NSCLC) accounts for ∼85% of all cases of lung cancer and has a poor prognosis. Activating transcription factor 3 (ATF3), a member of the ATF/cyclic adenosine monophosphate response element binding (ATF/cyclic response element binding) family of transcription factors, has been implicated in the pathogenesis of several types of cancer. However, whether the expression of ATF3 is aberrant in NSCLC and genetic variants, or DNA methylation of the gene contributes to the tumorigenesis of NSCLC, are largely unknown.